Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1401 studies found for:    "multiple sclerosis"
Show Display Options
RSS Create an RSS feed from your search for:
"multiple sclerosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
2 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
3 Recruiting A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis,;   Secondary Progressive Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis,;   Demyelinating Autoimmune Diseases,;   Nervous System Diseases
Interventions: Behavioral: Combined program;   Behavioral: Physiotherapy in private practice
4 Unknown  A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
5 Recruiting A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Conditions: Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Clinically Isolated Syndrome
6 Active, not recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BIIB041 (fampridine)
7 Recruiting Oral Guanabenz for Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: Guanabenz
8 Recruiting Plasma Exchanges in Multiple Sclerosis (MS) Relapses
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Acute Relapsing
Interventions: Procedure: plasma exchange;   Procedure: sham exchanges procedure
9 Enrolling by invitation Idebenone for Primary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Drug: Idebenone
10 Completed Natalizumab Treatment of Progressive Multiple Sclerosis
Conditions: Primary Progressive Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Intervention: Drug: Natalizumab
11 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
12 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
13 Active, not recruiting Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: DAC-HYP
14 Completed Safety Study of BIIB033 in Subjects With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BIIB033;   Drug: Placebo
15 Active, not recruiting A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Interventions: Drug: Fampridine;   Drug: Placebo
16 Completed Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
17 Active, not recruiting Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: XCEL-MC-ALPHA;   Drug: Placebo
18 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
19 Recruiting Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Cognitive Deficits;   Motor Deficits
Intervention: Device: tDCS
20 Completed Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon-1beta (Betaseron, BAY86-5046)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years